The Evolving Role of Aromatase Inhibitors in Adjuvant Breast Cancer Therapy
- 1 August 2005
- journal article
- case report
- Published by Elsevier in Clinical Breast Cancer
- Vol. 6 (3) , 206-215
- https://doi.org/10.3816/cbc.2005.n.022
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Mechanisms of Tamoxifen Resistance: Increased Estrogen Receptor-HER2/neu Cross-Talk in ER/HER2-Positive Breast CancerJNCI Journal of the National Cancer Institute, 2004
- Aromatase Inhibitors for Breast Cancer in Postmenopausal WomenThe Oncologist, 2004
- A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast CancerNew England Journal of Medicine, 2004
- A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast CancerNew England Journal of Medicine, 2003
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancerCancer, 2003
- Aromatase Inhibitors in Breast CancerNew England Journal of Medicine, 2003
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002
- Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinomaCancer, 2001
- Tamoxifen in the Treatment of Breast CancerNew England Journal of Medicine, 1998
- Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 1998